Table 1. Comparisons of each regimen with Gemcitabine (G).
| Regimen Name | OS Hazard Ratio when compared with G | Projected Median OS (months)* | NNT at 6 months when compared with G | NNT at 1 year when compared with G |
| FOLFIRINOX | 0.57 | 9.9 | 6 | 5 |
| G + nab-paclitaxel | 0.72 | 7.8 | 9 | 9 |
| G + S1 | 0.79 | 7.2 | 12 | 12 |
| G + erlotinib | 0.82 | 6.9 | 15 | 14 |
| G + capecitabine | 0.83 | 6.8 | 16 | 15 |
| G + oxaliplatin | 0.88 | 6.4 | 23 | 23 |
| G + fluorouracil | 0.94 | 6.0 | 46 | 47 |
| G + cisplatin | 0.98 | 5.8 | 141 | 146 |
| G | — | 5.65 | — | — |
Footnotes: Hazard ratios when comparing each regimen with Gemcitabine (G), projected median overall survival (OS), number needed to treat (NNT) at 6 months and 1 year when compared with G. Projected median OS was calculated using a median OS of 5.65 months as reported by Buris et al (5). Survival and NNT was estimated based on the mixed treatment comparisons results and the method by Altman and Andersen (22).